- Home
- IONS vs HSIC Comparison
IONS vs HSIC Comparison
Compare IONS & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- HSIC
- Stock Information
- Founded
- IONS 1989
- HSIC 1932
- Country
- IONS United States
- HSIC United States
- Employees
- IONS N/A
- HSIC N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- HSIC Medical Specialities
- Sector
- IONS Health Care
- HSIC Health Care
- Exchange
- IONS Nasdaq
- HSIC Nasdaq
- Market Cap
- IONS 6.8B
- HSIC 8.0B
- IPO Year
- IONS 1991
- HSIC 1995
- Fundamental
- Price
- IONS $69.15
- HSIC $65.66
- Analyst Decision
- IONS Strong Buy
- HSIC Buy
- Analyst Count
- IONS 18
- HSIC 12
- Target Price
- IONS $72.83
- HSIC $76.25
- AVG Volume (30 Days)
- IONS 2.2M
- HSIC 1.5M
- Earning Date
- IONS 11-05-2025
- HSIC 11-04-2025
- Dividend Yield
- IONS N/A
- HSIC N/A
- EPS Growth
- IONS N/A
- HSIC 15.03
- EPS
- IONS N/A
- HSIC 3.11
- Revenue
- IONS $944,050,000.00
- HSIC $12,773,000,000.00
- Revenue This Year
- IONS $24.01
- HSIC $4.62
- Revenue Next Year
- IONS $4.06
- HSIC $3.55
- P/E Ratio
- IONS N/A
- HSIC $21.56
- Revenue Growth
- IONS 16.05
- HSIC 2.29
- 52 Week Low
- IONS $23.95
- HSIC $60.56
- 52 Week High
- IONS $69.25
- HSIC $82.49
- Technical
- Relative Strength Index (RSI)
- IONS 80.12
- HSIC 42.00
- Support Level
- IONS $61.03
- HSIC $65.20
- Resistance Level
- IONS $63.18
- HSIC $67.35
- Average True Range (ATR)
- IONS 1.63
- HSIC 1.39
- MACD
- IONS 0.02
- HSIC -0.14
- Stochastic Oscillator
- IONS 89.41
- HSIC 14.22
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.